CRISPR/Cas9, the gene editing tool that enables highly-efficient and precise modifications to DNA, has been a disruptive force in scientific research and drug discovery. While CRISPR possesses significant ease-of-use advantages over former gene editing methods, it is an advanced tool requiring careful experimental design for optimal outcomes.
Charles River biologists employ CRISPR for target screening alone or alongside RNAi screening with our shRNA library (SilenceSelect®) and to create complex custom knock-in and knockout cell lines with applications throughout the drug discovery continuum:
Target discovery and validation: gRNA library screening, disease-relevant phenotypic screening
Hit discovery: Generate knock-in cell lines expressing your gene of interest to use in cell-based HTS assays
Hit-to-lead: Precision mutagenesis of tumor cell lines
Lead-to-candidate: ES cell modification for custom transgenic mouse models
Charles River acquired a license from the Broad Institute to work with CRISPR in May 2014.